AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03919617
Drug: REMD-477
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
Trial: NCT02652234
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
Trial: NCT01195675
Drug: BI 10773 (low)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01195675
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01195675
Drug: BI 10773 (high)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT02007889
Drug: L-carnitine
RxNorm normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
Trial: NCT02920398
Drug: turoctocog alfa pegol
RxNorm normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
Trial: NCT02642484
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gapapentin twice daily
Trial: NCT02642484
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium carbonate twice daily
Trial: NCT03572413
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
Trial: NCT01520896
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 400 mg
Trial: NCT01512472
Drug: degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
Trial: NCT03675672
Drug: Misoprostol Oral Tablet
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 200mcg
Trial: NCT00367120
Drug: Amoxicillin/Clavulanate
RxNorm normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02211144
Drug: BIBR 796 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004548
Drug: Metatinib Tromethamine
RxNorm normalized name: Tromethamine
DrugBank: Tromethamine (DB03754)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03739541
Drug: [14C]-Benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose level of 100 mg; 200 μCi (7.4 MBq)
Trial: NCT00416169
Drug: galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02080455
Drug: lomitapide
RxNorm normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg dose
Trial: NCT02080455
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg
Trial: NCT01898676
Drug: Divalproex Sodium Extended-release 250mg
RxNorm normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
Trial: NCT01898676
Drug: DEPAKOTE 250mg
RxNorm normalized name: Depakote 250mg Delayed-Release Tablet
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
Trial: NCT02729103
Drug: Xofigo (Radium 223 dichloride,BAY88-8223)
RxNorm normalized name: Xofigo
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retrospective claims analysis. Descriptive analyses of treatment patterns.
Trial: NCT01001572
Drug: Valsartan/amlodipine 160/5 mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
Trial: NCT01474499
Drug: Glycerine
RxNorm normalized name: Glycerine
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01001572
Drug: Valsartan 160 mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160 mg capsule taken orally once daily.
Trial: NCT02039960
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
Trial: NCT04157140
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Trial: NCT02997371
Drug: Anakinra Prefilled Syringe
RxNorm normalized name: anakinra Prefilled Syringe
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration as initially intravenous injection followed by a intravenous infusion
Trial: NCT00419783
Drug: bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg tablets.
Trial: NCT00419783
Drug: Bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 100 mg (5 tablets of 20 mg)
Trial: NCT00419783
Drug: Bilastine & Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
Trial: NCT00419783
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule containing moxifloxacin 400 mg tablet
Trial: NCT02918760
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
Trial: NCT03267940
Drug: GEM
RxNorm normalized name: Gemzar
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GEM will be administered as per the schedule specified in the respective arms.
Trial: NCT03267940
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the schedule specified in the respective arms.
Trial: NCT02070796
Drug: Rotigotine PR2.2.1
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.
Trial: NCT00052754
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02849184
Drug: suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
Trial: NCT00946114
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 20mg, TID, 112 weeks at the maximum
Trial: NCT00946114
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
Trial: NCT00135967
Drug: prednisone 0,5 mg/kg orally on alternate days
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03809156
Drug: Riociguat Oral Product
RxNorm normalized name: riociguat Oral Product
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
Trial: NCT00541723
Drug: IncobotulinumtoxinA (Xeomin)
RxNorm normalized name: incobotulinumtoxinA Injection [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
Trial: NCT03211650
Drug: hyaluronic Acid + platelet-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
Trial: NCT03211650
Drug: hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of hyaluronic acid
Trial: NCT03211650
Drug: platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of platelet-rich plasma
Trial: NCT01530009
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
Trial: NCT01783587
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Taken orally once per day
Trial: NCT01783587
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg/m2, given intravenously once per week
Trial: NCT01800422
Drug: telapristone acetate
RxNorm normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02905760
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)
Trial: NCT02905760
Drug: Placebo furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial).
Trial: NCT01216384
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
Trial: NCT00713726
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
Trial: NCT01340196
Drug: tenofovir/BI 201335
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
Trial: NCT01561521
Drug: AKF-1
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
Trial: NCT01561521
Drug: AKF-1
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
Trial: NCT01561521
Drug: AKF-1
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop 0% in each eye at 2 separate times during a 14 day period
Trial: NCT00183625
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00183625
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03876119
Drug: Intraarterial alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions.
Trial: NCT00749723
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
Trial: NCT00749723
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
Trial: NCT00749723
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
Trial: NCT00749723
Drug: thiotepa, carboplatin, etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high dose chemotherapy followed by to autologous stem cell transplantation
Trial: NCT00749723
Drug: temozolomide, thiotepa
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high dose chemotherapy followed by autologous stem cell transplantation
Trial: NCT00749723
Drug: intraventricular etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
Trial: NCT00749723
Drug: trofosfamide, etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
Trial: NCT03386487
Drug: PF 04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be administered at 4mg by mouth daily for eight weeks.
Trial: NCT04381169
Drug: Lactated Ringer Solution
RxNorm normalized name: lactate
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
Trial: NCT03559647
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Trial: NCT00895674
Drug: Nexavar (Sorafenib, BAY43-9006)
RxNorm normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a diagnosis of advanced RCC
Trial: NCT02591199
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06248554
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
Trial: NCT01144949
Drug: silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
Trial: NCT02008292
Drug: Physostigmine
RxNorm normalized name: PHYSOSTIGMINE
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive physostigmine to induce elevated ACh levels in the brain.
Trial: NCT02881762
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
Trial: NCT04213222
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab combined with chemotherapy
Trial: NCT00998088
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively
Trial: NCT01631903
Drug: telepristone acetate 3 mg
RxNorm normalized name: Estradiol 3-acetate
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg, vaginal capsule, once daily for 3 months
Trial: NCT01631903
Drug: telepristone acetate 6 mg
RxNorm normalized name: tocopherol acetate 6 UNT
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg, vaginal capsule, once daily for 3 months
Trial: NCT00230451
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00230451
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00230451
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01390857
Drug: Valaciclovir
RxNorm normalized name: valaciclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03238625
Drug: Lidocaine and sodium bicarbonate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and sodium bicarbonate ratio 3:1
Trial: NCT03238625
Drug: Lidocaine and sodium bicarbonate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and sodium bicarbonate ratio 9:1
Trial: NCT03238625
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection
Trial: NCT04282902
Drug: pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
Trial: NCT03238482
Drug: salmeterol-fluticasone
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Seretide Diskus 50/250 µg/dose
Trial: NCT03238625
Drug: Sodium cloride 0.9%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03238482
Drug: salmeterol-fluticasone
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
Trial: NCT03238482
Drug: salmeterol-fluticasone
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
Trial: NCT03238482
Drug: salmeterol-fluticasone
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
Trial: NCT04501224
Drug: Tenofovir alafenamide fumarate
RxNorm normalized name: Tenofovir Alafenamide fumarate
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients would take tenofovir alafenamide fumarate, 25mg，once per day
Trial: NCT04501224
Drug: Entecavir or Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
Trial: NCT02943655
Drug: combined contraceptive pills (microcept)
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral combined contraceptive once daily